US › Healthcare

Pyxis Oncology Inc (PYXS)

US · Healthcare · Biotechnology

$3.41+2.10%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-25.3M

EPS

$-0.40

EPS estimate

$-0.34

EPS came in at -0.40 against a street estimate of -0.34 — a miss of 17.6%.

Key statistics

Market cap

$278.6M

Forward P/E

0.0

P/B

24.28

Book value

$0.18

EPS (TTM)

$-1.40

52-week high

$5.55

52-week low

$1.03

50-day MA

$3.04

200-day MA

$2.23

Beta

1.34

Analyst view

Analysts rate Pyxis Oncology Inc a buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $8.44.

Shareholding

Insiders

13.53%

Institutions

42.50%

Largest institutional holders

Fund	Stake
GordonMD Global Investments LP	12.02%
Pfizer Inc	8.43%
LAURION CAPITAL MANAGEMENT LP	5.99%
Vanguard Capital Management, LLC	2.44%
Atle Fund Management AB	1.16%
683 Capital Management LLC	1.07%
Renaissance Technologies Corp	1.07%
Palo Alto Investors, LLC	1.04%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pyxis Oncology Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.